1. Home
  2. CAPR vs GFUZ Comparison

CAPR vs GFUZ Comparison

Compare CAPR & GFUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$7.60

Market Cap

584.9M

Sector

Health Care

ML Signal

N/A

GFUZ

General Fusion Group Ltd. Common Shares

N/A

Current Price

$4.21

Market Cap

687.0M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
GFUZ
Founded
2005
2002
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Electric Utilities: Central
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
584.9M
687.0M
IPO Year
2011
2025

Fundamental Metrics

Financial Performance
Metric
CAPR
GFUZ
Price
$7.60
$4.21
Analyst Decision
Buy
Analyst Count
10
0
Target Price
★ $27.25
N/A
AVG Volume (30 Days)
★ 4.2M
97.8K
Earning Date
11-10-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$85.77
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.96
$4.60
52 Week High
$40.37
$11.00

Technical Indicators

Market Signals
Indicator
CAPR
GFUZ
Relative Strength Index (RSI) 48.38 26.25
Support Level $7.78 N/A
Resistance Level $10.62 $6.34
Average True Range (ATR) 1.18 0.44
MACD -0.11 -0.06
Stochastic Oscillator 19.61 0.00

Price Performance

Historical Comparison
CAPR
GFUZ

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About GFUZ General Fusion Group Ltd. Common Shares

General Fusion Group Ltd is focused on developing fusion energy technology based on Magnetized Target Fusion (MTF), which combines magnetic confinement and mechanical compression to achieve fusion conditions. It operates a large-scale demonstration system, Lawson Machine 26 (LM26), intended to validate elements of its technology and support the development of commercial fusion power plants for electricity generation.

Share on Social Networks: